Related references
Note: Only part of the references are listed.
Article
Medicine, General & Internal
Feargal J. Ryan et al.
Summary: A study found that recovered individuals, even those with mild cases, may experience persistent symptoms for months after infection, known as long COVID. An integrated analysis of 69 patients recovering from COVID-19 revealed variations in cellular and gene expression levels that may explain the persistence of these long-term effects.
Letter
Rheumatology
Alexandros A. Drosos et al.
CLINICAL RHEUMATOLOGY
(2022)
Article
Infectious Diseases
Michela Antonelli et al.
Summary: Despite the high efficacy of COVID-19 vaccines, some individuals still become infected with SARS-CoV-2 post-vaccination. Risk factors for post-vaccination infection include frailty in older adults, living in deprived areas, and obesity. Vaccination is associated with reduced odds of severe symptoms and long-duration illness. The findings suggest the importance of targeting at-risk populations and maintaining infection control measures even in vaccinated individuals.
LANCET INFECTIOUS DISEASES
(2022)
Article
Immunology
Nisreen A. Alwan
Summary: The importance of the lived experience of Long COVID
NATURE REVIEWS IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Merryn Voysey et al.
Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.
Article
Multidisciplinary Sciences
Christian Gaebler et al.
Summary: After infection with SARS-CoV-2, antibody levels against the spike protein decrease significantly, but the number of memory B cells remain unchanged, indicating an evolving humoral response at 6.2 months after infection.
Article
Medicine, General & Internal
Ann R. Falsey et al.
Summary: The clinical trial in the United States, Chile, and Peru showed that the AZD1222 vaccine was both safe and effective in preventing symptomatic and severe Covid-19 cases, with an overall estimated efficacy of 74% and a higher efficacy of 83.5% in participants 65 years of age or older. The high vaccine efficacy was consistent across various demographic subgroups, and antibodies increased significantly after each dose.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Infectious Diseases
Cristina Menni et al.
Summary: This study investigated the safety and effectiveness of the BNT162b2 and ChAdOx1 nCoV-19 vaccines in a UK community setting. The results showed that the frequencies of side effects from these vaccines were lower than reported in clinical trials, and a significant reduction in the risk of SARS-CoV-2 infection was observed starting at 12 days after vaccination.
LANCET INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Jamie Lopez Bernal et al.
Summary: This study estimated the real-world effectiveness of Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed COVID-19 symptoms, hospital admissions, and deaths. The vaccines showed significant reduction in symptomatic COVID-19 among older adults and further protection against severe disease. Both vaccines demonstrated similar effects and protection was maintained for over 6 weeks.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Primary Health Care
Alex J. Walker et al.
Summary: Recording of long COVID in primary care in England is low and shows significant variation between practices. Possible factors contributing to this include lack of patient presentation, differing diagnostic thresholds among clinicians and patients, and challenges with the design and communication of diagnostic codes. It is recommended to increase awareness of diagnostic codes to support research and service planning, and to conduct qualitative surveys to better understand clinicians' perspectives on diagnosis.
BRITISH JOURNAL OF GENERAL PRACTICE
(2021)
Article
Immunology
Javier Garcia-Abellan et al.
Summary: Long-COVID is associated with weak anti-SARS-CoV-2 antibody response, severity of illness, and female gender. Late clinical events and persistent symptoms in the medium and long term occur in a significant proportion of patients hospitalized for COVID-19.
JOURNAL OF CLINICAL IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Emma Pritchard et al.
Summary: Results from the Office for National Statistics COVID-19 Infection Survey in the UK demonstrate that the ChAdOx1 nCoV-19 and BNT162b2 vaccines reduce the incidence of new SARS-CoV-2 infections by up to 65% with a single dose and up to 80% after two doses, with no significant differences in efficacy observed between the two vaccines.
Letter
Medicine, General & Internal
Ross J. Harris et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Meeting Abstract
Public, Environmental & Occupational Health
Nida Ziauddeen et al.
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH
(2021)
Article
Health Care Sciences & Services
Esperanza Miyake et al.
Summary: This study found that the greatest negative impacts on long-term Covid-19 sufferers come mainly from conflicting definitions of the virus and fears surrounding the Covid-19 vaccine. Key areas of concern include time/duration, symptoms/testing, emotional impact, and lack of support and resources.
Review
Public, Environmental & Occupational Health
Melina Michelen et al.
Summary: Long COVID is a complex condition with prolonged and heterogeneous symptoms, including weakness, general malaise, fatigue, concentration impairment, and breathlessness. Approximately 37% of patients reported reduced quality of life, and 26% of studies presented evidence of reduced pulmonary function. There is an urgent need for further studies to explore the etiology, risk factors, and biomarkers of long COVID in different populations and settings.
Article
Medicine, General & Internal
Hannah E. Davis et al.
Summary: Patients with Long COVID report prolonged, multisystem involvement and significant disability. By seven months, many patients have not yet recovered (mainly from systemic and neurological/cognitive symptoms), have not returned to previous levels of work, and continue to experience significant symptom burden.
Article
Public, Environmental & Occupational Health
James Lopez Bernal et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
(2017)
Article
Mathematical & Computational Biology
Peter C. Austin
STATISTICS IN MEDICINE
(2009)
